Skip to main content
HYUNDAI BIOSCIENCE CO., LTD. logo

HYUNDAI BIOSCIENCE CO., LTD. — Investor Relations & Filings

Ticker · 048410 ISIN · KR7048410005 KO Professional, scientific and technical activities
Open in API
Filings indexed 288 across all filing types
Latest filing 2019-03-25 Board/Management Inform…
Country KR South Korea
Listing KO 048410

About HYUNDAI BIOSCIENCE CO., LTD.

http://www.hyundaibioscience.com/eindex…

HYUNDAI BIOSCIENCE CO., LTD. is a biotechnology company focused on developing innovative therapeutics using its proprietary drug delivery system (DDS) technology. The company's core science is based on organic-inorganic hybrid technologies designed to safely and effectively deliver active ingredients. Its main development pipeline includes CP-COV03, a broad-spectrum antiviral agent that enhances cellular autophagy to combat viral infections, and Polytaxel, an anticancer drug candidate developed with polymer transfer technologies to reduce toxicity. The company's primary focus is on creating novel treatments for viral diseases and cancer.

Recent filings

Filing Released Lang Actions
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a regulatory filing submitted to the Financial Services Commission/Korea Exchange regarding the appointment or dismissal of an outside director (사외이사의 선임ㆍ해임). This type of corporate governance disclosure specifically relates to changes in the board of directors, which falls under the 'Board/Management Information' category.
2019-03-25 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official report of the results of a General Meeting of Shareholders (AGM) for Hyundai Bioscience. It details the approval of financial statements, dividend resolutions, election of directors, and other agenda items voted upon during the meeting. This fits the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA) as it provides the official outcome of shareholder votes.
2019-03-25 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 95% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on the Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to directors and employees, including the number of shares, exercise price, and valuation methodology. This type of disclosure regarding equity-based compensation and capital structure changes falls under the category of 'Share Issue/Capital Change' (SHA) within the provided classification schema.
2019-03-25 Korean
감사보고서제출
Report Publication Announcement Classification · 95% confidence The document is a formal announcement titled '감사보고서 제출' (Submission of Audit Report) by Hyundai Bio. It provides a summary of the audit opinion (which is 'Appropriate' or 'Unqualified') and key financial data (assets, liabilities, equity, profit/loss) for the current and previous fiscal years. According to the 'Menu vs Meal' rule, this document is an announcement of the audit report submission rather than the full audit report itself, as it summarizes the findings and provides the filing date. Therefore, it is classified as a Report Publication Announcement (RPA).
2019-03-15 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Solicitation of Proxy' (위임장 권유) filed by Hyundai Bioscience Co., Ltd. for its 19th Annual General Meeting. It contains detailed information about the solicitor, the purpose of the solicitation, the meeting agenda (including financial statements), and detailed financial data (balance sheets, income statements, cash flow statements). In the context of Korean regulatory filings (DART), this is a 'Proxy Solicitation' document, which falls under the 'Proxy Solicitation & Information Statement' category.
2019-03-11 Korean
주주총회소집결의
AGM Information Classification · 97% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for Hyundai Bioscience. It outlines the date, location, and specific agenda items (proposals) for the upcoming meeting, including financial statement approval, board appointments, and remuneration limits. This type of document is provided to shareholders to inform them of the meeting and solicit their participation/votes, which aligns with the definition of a Proxy Solicitation & Information Statement.
2019-03-08 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.